Skip to main content

A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib

Tumor Biology volume 37, pages 2365–2378 (2016)Cite this article

Abstract

Chronic myeloid leukemia (CML) is a type of hematological malignancy that is characterized by the generation of Philadelphia chromosome encoding BCR/ABL oncoprotein. Tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, and dasatinib, are used for the frontline therapy of CML. Development of resistance against these TKIs in the patients bearing T315I mutation is a major obstacle in CML therapy. Ponatinib, the third-generation TKI, is novel drug that is effective even in CML patients with T315I mutation. The exact mechanism of ponatinib in CML has been still unknown. In this study, we aimed to determine the potential mechanisms and structural metabolic changes activated by ponatinib treatment in imatinib-sensitive K562 human CML cell lines and 3 μM-imatinib-resistant K562/IMA3 CML cell lines generated at our lab. Apoptotic and antiproliferative effects of ponatinib on imatinib-sensitive and 3 μM-imatinib-resistant K562/IMA3 CML cells were determined by proliferation and apoptosis assays. Additionally, the effects of ponatinib on macromolecules and lipid profiles were also analyzed using Fourier transform infrared spectroscopy (FTIR). Our results revealed that ponatinib inhibited cell proliferation and induced apoptosis as determined by loss of mitochondrial membrane potential, increased caspase-3 enzyme activity, and transfer of phosphatidylserine to the plasma membrane in both K562 and K562/IMA-3 cells. Furthermore, cell cycle analyses revealed that ponatinib arrested K562 and K562/IMA-3 cells at G1 phase. Moreover, ponatinib treatment created a more ordered nucleic acid structure in the resistant cells. Although the lipid to protein ratio increased in imatinib-sensitive K562 cells with a little decrease in the K562/IMA-3 cells, ponatinib treatment indicated significant changes in the lipid composition such as a significant increase in the cellular cholesterol amounts much more in the K562/IMA-3 cells than the sensitive counterparts. Unsaturation in lipids was higher in the resistant cells; however, increases in lipids without phosphate and the number of acyl chains were much higher in the K562 cells. Taken together, all these results showed powerful antiproliferative and apoptotic effects of ponatinib in both imatinib-sensitive and imatinib-resistant CML cells in a dose-dependent manner, and hence, the use of ponatinib for the treatment of TKI-resistant CML patients may be an effective treatment approach in the clinic. More importantly, these results showed that FTIR spectroscopy can detect drug-induced physiological changes in cancer drug resistance.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14
Fig. 15
Fig. 16
Fig. 17

References

  1. Cea M, Cagnetta A, Nencioni A, Gobbi M, Patrone F. New insights into biology of chronic myeloid leukemia: implications in therapy. Curr Cancer Drug Targets. 2013;13:711–23.

    CAS  Article  PubMed  Google Scholar 

  2. Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: past, present, and future. Am J Hematol. 2009;84:287–93.

    CAS  Article  PubMed  Google Scholar 

  3. O’Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, et al. Chronic myelogenous leukemia, version 1.2014. J Natl Compr Cancer Netw. 2013;11:1327–40.

    Google Scholar 

  4. Kimura S, Ando T, Kojima K. Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol. 2014;19:3–9.

    CAS  Article  PubMed  Google Scholar 

  5. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7:345–56.

    CAS  Article  PubMed  Google Scholar 

  6. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 2002;62:7149–53.

    PubMed  Google Scholar 

  7. O’Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401–12.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Jain P, Kantarjian H, Cortes J. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options in Oncol. 2013;14:127–43.

    Article  Google Scholar 

  9. Dogan A, Ergen K, Budak F, Severcan F. Evaluation of disseminated candidiasis on an experimental animal model: a Fourier transform infrared study. Appl Spectrosc. 2007;61:199–203.

    CAS  Article  PubMed  Google Scholar 

  10. Cakmak G, Togan I, Severcan F. 17Beta-estradiol induced compositional, structural and functional changes in rainbow trout liver, revealed by FT-IR spectroscopy: a comparative study with nonylphenol. Aquat Toxicol. 2006;77:53–63.

    CAS  Article  PubMed  Google Scholar 

  11. Kneipp J, Lasch P, Baldauf E, et al. Detection of pathological molecular alterations in scrapie-infected hamster brain by Fourier transform infrared (FT-IR) spectroscopy. Biochim Biophys Acta. 2000;1501:189–99.

    CAS  Article  PubMed  Google Scholar 

  12. Gaigneaux A, Ruysschaert JM, Goormaghtigh E. Infrared spectroscopy as a tool for discrimination between sensitive and multiresistant K562 cells. Eur J Biochem. 2002;269:1968–73.

    CAS  Article  PubMed  Google Scholar 

  13. Le Gal JM, Morjani H, Manfait M. Ultrastructural appraisal of the multidrug resistance in K562 and LR73 cell lines from Fourier transform infrared spectroscopy. Cancer Res. 1993;53:3681–6.

    PubMed  Google Scholar 

  14. Piskin O, Ozcan MA, Ozsan GH, Ates H, Demirkan F, Alacacioglu I, et al. Synergistic effect of imatinib mesylate and fludarabine combination on Philadelphia chromosome-positive chronic myeloid leukemia cell lines. Turk J Haematol. 2007;24:23–7.

    CAS  PubMed  Google Scholar 

  15. Gokbulut AA, Apohan E, Baran Y. Resveratrol and quercetin-induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest. Hematology. 2013;18(3):144–50.

    CAS  Article  PubMed  Google Scholar 

  16. Baran Y, Bielawski J, Gunduz U, Ogretmen B. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. J Cancer Res Clin Oncol. 2011;137(10):1535–44.

    CAS  Article  PubMed  Google Scholar 

  17. Goktas S, Baran Y, Ural AU, Yazici S, Aydur E, Basal S, et al. Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells. Urology. 2010;75(4):793–8.

    Article  PubMed  Google Scholar 

  18. Petkovic M, Vocks A, Müller M, Schiller J, Arnhold J. Comparison of different procedures for the lipid extraction from HL-60 cells: a MALDI-TOF mass spectrometric study. Z Naturforsch. 2005;60c:143–51.

    Google Scholar 

  19. Ceylan C, Karacicek B. Structural and functional characterization of solution, gel, and aggregated forms of trypsin in organic solvent-assisted and pH-induced phase changes/tripsin çözelti, jel ve agregat formlarının organik çözgen içeren ve pH-tektiklenmiş faz geçişlerinde yapısal ve fonksiyonel incelenmesi. Turk J Biochem. 2015;40:81–7.

    CAS  Google Scholar 

  20. Baran Y, Ceylan C, Camgoz A. The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopy. Biomed Pharmacother. 2013;67:221–7.

    CAS  Article  PubMed  Google Scholar 

  21. Melin AM, Perromat A, Deleris G. Pharmacologic application of Fourier transform IR spectroscopy: in vivo toxicity of carbon tetrachloride on rat liver. Biopolymers. 2000;57:160–8.

    CAS  Article  PubMed  Google Scholar 

  22. Nara M, Okazaki M, Kagi H. Infrared study of human serum very-low-density and low-density lipoproteins. Implication of esterified lipid C O stretching bands for characterizing lipoproteins. Chem Phys Lipids. 2002;117:1–6.

    CAS  Article  PubMed  Google Scholar 

  23. Voortman G, Gerrits J, Altavilla M, Henning M, Van BL, Hessels J. Quantitative determination of faecal fatty acids and triglycerides by Fourier transform infrared analysis with a sodium chloride transmission flow cell. Clin Chem Lab Med. 2002;40:795–8.

    CAS  Article  PubMed  Google Scholar 

  24. Manoharan R, Baraga JJ, Rava RP, Dasari RR, Fitzmaurice M, Feld MS. Biochemical analysis and mapping of atherosclerotic human artery using FT-IR microspectroscopy. Atherosclerosis. 1993;103:181–93.

    CAS  Article  PubMed  Google Scholar 

  25. Jackson M, Ramjiawan B, Hewko M, Mantsch HH. Infrared microscopic functional group mapping and spectral clustering analysis of hypercholesterolemic rabbit liver. Cell Mol Biol. 1998;44:89–98.

    CAS  PubMed  Google Scholar 

  26. Wang JJ, Chi CW, Lin SY, Chern YT. Conformational changes in gastric carcinoma cell membrane protein correlated to cell viability after treatment with adamantyl maleimide. Anticancer Res. 1997;17:3473–7.

    CAS  PubMed  Google Scholar 

  27. Wong PT, Wong RK, Caputo TA, Godwin TA, Rigas B. Infrared spectroscopy of exfoliated human cervical cells: evidence of extensive structural changes during carcinogenesis. Proc Natl Acad Sci U S A. 1991;88:10988–92.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. Chiriboga L, Xie P, Vigorita V, Zarou D, Zakim D, Diem M. Infrared spectroscopy of human tissue. II.A comparative study of spectra of biopsies of cervical squamous epithelium and of exfoliated cervical cells. Biospectroscopy. 1998;4:55–9.

    CAS  Article  PubMed  Google Scholar 

  29. Ci YX, Gao TY, Feng J, Guo JQ. Fourier transform infrared spectroscopic characterization of human breast tissue: implications for breast cancer diagnosis. Appl Spectrosc. 1999;53:312–5.

    CAS  Article  Google Scholar 

  30. Dovbeshko GI, Gridina NY, Kruglova EB, Pashchuk OP. FTIR spectroscopy studies of nucleic acid damage. Talanta. 2000;53:233–46.

    CAS  Article  PubMed  Google Scholar 

  31. Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: past, present, and future. Am J Hematol. 2009;84:287–93.

    CAS  Article  PubMed  Google Scholar 

  32. Frazer R, Irvine AE, McMullin MF. Chronic myeloid leukaemia in the 21st century. Ulster Med J. 2007;76(1):8–17.

    PubMed  PubMed Central  Google Scholar 

  33. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075–88.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. Cortes JE, Kim DW, Pinilla-Ibarz J, Le Coutre PD, Chuah C, Nicolini FE, Paquette R, Apperley JF, DiPersio JF, Khoury HJ, Rea D, Talpaz M, DeAngelo DJ, Abruzzese E, Baccarani M, Mueller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Turner CD, Rivera VM, Clackson T, Haluska F, Kantarjian HM, The PACE Study Group. Initial findings from the PACE Trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. ASH Meeting 2012; Abstract 163.

  35. Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, et al. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib. Oncotarget. 2012;3:1557–65.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Takahashi H, French SW, Wong PT. Alterations in hepatic lipids and proteins by chronic ethanol intake: a high-pressure Fourier transform infrared spectroscopic study on alcoholic liver disease in the rat. Alcohol Clin Exp Res. 1991;15:219–23.

    CAS  Article  PubMed  Google Scholar 

  37. Kim HH, Kim T, Kim E, Park JK, Park SJ, Joo H. The mitochondrial Warburg effect: a cancer enigma. Interdisciplinary Bio Central. 2009;1:1–7.

    Google Scholar 

  38. Severcan F, Toyran N, Kaptan N, Turan B. Fourier transform infrared study of the effect of diabetes on rat liver and heart tissues in the CH region. Talanta. 2000;53:55–9.

    CAS  Article  PubMed  Google Scholar 

  39. Schuldes H, Dolderer JH, Zimmer G, Knobloch J, Bickeboller R, Jonas D, et al. Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts. Eur J Cancer. 2001;37:660–7.

    CAS  Article  PubMed  Google Scholar 

  40. Tsvetkova NM, Horvath I, Torok Z, Wolkers WF, Balogi Z, Shigapova N, et al. Small heat-shock proteins regulate membrane lipid polymorphism. Proc Natl Acad Sci U S A. 2002;99:13504–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  41. Colagar A, Chaichi M, Khadjvand T. Fourier transform infrared microspectroscopy as a diagnostic tool for distinguishing between normal and malignant human gastric tissue. J Biosci. 2011;36:669–77.

    Article  PubMed  Google Scholar 

  42. Kochan K, Maslak E, Chlopicki S, Baranska M. FT-IR imaging for quantitative determination of liver fat content in non-alcoholic fatty liver. Analyst. 2015;140(15):4997–5002.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was partly supported by TUBITAK project number 107S317 to Y.B. We thank İzmir Institute of Technology, Bioengineering and Biotechnology Application and Research Center for their assistance.

Conflicts of interest

None

Author information

Affiliations

  1. Department of Molecular Biology and Genetics, İzmir Institute of Technology, Urla, 35430, İzmir, Turkey

    Melis Kartal Yandim & Yusuf Baran

  2. Department of Food Engineering, İzmir Institute of Technology, Urla, 35430, İzmir, Turkey

    Cagatay Ceylan & Efe Elmas

  3. Department of Molecular Biology and Genetics, Faculty of Life and Natural Sciences, Abdullah Gul University, Kayseri, Turkey

    Yusuf Baran

Authors
  1. Melis Kartal Yandim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cagatay Ceylan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Efe Elmas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yusuf Baran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Cagatay Ceylan or Yusuf Baran.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yandim, M.K., Ceylan, C., Elmas, E. et al. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib. Tumor Biol. 37, 2365–2378 (2016). https://doi.org/10.1007/s13277-015-4015-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4015-9

Keywords

  • Ponatinib
  • Chronic myeloid leukemia (CML)
  • Multidrug resistance (MDR)
  • Imatinib
  • Fourier transform infrared spectroscopy (FTIR)